Diabetes subgroup analysis actually shows slightly lower weight loss in diabetic patients (19.7% at 8mg dose) compared to non-diabetic patients (24.2% at 12mg dose)
Contributions of treatment-induced reductions in triglyceride and increases in HDL cholesterol to reductions in CV risk are less directly demonstrated compared to the relationship with LDL cholesterol [18] but may signal improvements in fasting and meal-related lipid handling that favorably impact cardiovascular risk [32, 33]
The GLP-1 and GIP receptors targeted by tirzepatide are found in various tissues, including the lining of blood vessels
Nasal delivery process can be feasible for select large molecules like GLP-1, but success is highly molecule and formulation dependent, not a universal solution though
You will leave with the system and operational plans necessary for your clinic to grow and scale
Based on three common endpoints used in the treatment of T2D, this approach allows the short-term cost-effectiveness of interventions to be evaluated in a clinically relevant manner that is both straightforward and transparent [17]